Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
QuintilesIMS
Chinese Patent Office
Argus Health
Queensland Health
US Department of Justice
Colorcon
Citi

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,802,735

« Back to Dashboard

Which drugs does patent 8,802,735 protect, and when does it expire?

Patent 8,802,735 protects AUBAGIO and is included in one NDA.

This patent has forty-seven patent family members in thirty-seven countries.
Summary for Patent: 8,802,735
Title:(Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Abstract: The invention relates to solid pharmaceutical compositions comprising (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.
Inventor(s): Hauck; Gerrit (Frankfurt am Main, DE)
Assignee: Sanofi (Paris, FR)
Application Number:13/422,494
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 8,802,735

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi Aventis Us AUBAGIO teriflunomide TABLET;ORAL 202992-001 Sep 12, 2012 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Sanofi Aventis Us AUBAGIO teriflunomide TABLET;ORAL 202992-002 Sep 12, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,802,735

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
09290716Sep 18, 2009

International Patents Family Members for US Patent 8,802,735

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 078383 ➤ Try a Free Trial
Australia 2010297357 ➤ Try a Free Trial
Australia 2013257516 ➤ Try a Free Trial
Brazil 112012006184 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Accenture
Cantor Fitzgerald
Baxter
Chinese Patent Office
Mallinckrodt
AstraZeneca
Chubb
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.